Comparative Pharmacology
Head-to-head clinical analysis: COLESTID versus QUESTRAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: COLESTID versus QUESTRAN.
COLESTID vs QUESTRAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds bile acids in the intestine, forming an insoluble complex that is excreted in the feces, thereby increasing fecal loss of bile acids and reducing enterohepatic circulation of bile salts. This leads to increased hepatic conversion of cholesterol to bile acids, reduction in hepatic cholesterol stores, and decreased plasma LDL cholesterol levels.
Binds bile acids in the intestine, forming an insoluble complex that is excreted in feces, thereby preventing their enterohepatic reabsorption and increasing hepatic LDL receptor activity and cholesterol catabolism.
5-10 g orally once or twice daily, maximum 30 g/day.
Questran (cholestyramine) is administered orally. The typical adult dose is 4 grams (one packet or one level scoop) once or twice daily, with a maximum of 24 grams per day. The powder should be mixed with at least 120 mL of fluid (e.g., water, juice).
None Documented
None Documented
Not applicable due to non-systemic action; local gastrointestinal half-life not clinically defined
Not applicable; the drug is not absorbed and does not have a systemic half-life. Clinical effect persists as long as the resin remains in the gut (approximately 6-8 hours per dose).
Primarily fecal (≥95%) as unchanged drug; minimal renal excretion (<5%)
Cholestyramine is not absorbed from the gastrointestinal tract; therefore, it is excreted entirely in the feces as the intact resin, with no renal or biliary excretion.
Category C
Category C
Bile Acid Sequestrant
Bile Acid Sequestrant